Archives

Divorce! Amylin Pharma and Lilly Call It Quits Over Diabetes Drug

The contentious — and litigious — diabetes relationship between Amylin Pharmaceuticals(AMLN) and Eli Lilly(LLY) has come to an end. /* Promo Alert */ .aapAlertPromo { background:#fff url(‘http://i.thestreet-static.com/files/tsc/v2008/css/images/aap_articlePromo.jpg’) no-repeat; width:340px; height:70px; color:#000; } .aapAlertPromo a.findout { width:180px; font: bold 12px arial,helvetica,sans-serif; margin-left:15px; margin-top:17px; color:#000; float:left; } #story .aapAlertPromo2 { background:#fff url(‘http://i.thestreet-static.com/files/tsc/v2008/css/images/aap_articlePromo.jpg’) no-repeat; width:340px; height:70px; color:#000; } […]

Read More →
How Will Commitment Technology Affect the Credit Card Market?

by Sandeep Baliga Mastercard (MA) inControl allows a credit card user to set up a monthly budget so charges are rejected once the user’s expenditures per month reach the budget. Useless for the fully rational consumer and a godsend for the accidentally-profligate and the constantly-tempted shopper. Citibank (C) is set to introduce this product in […]

Read More →
Kaufman Launches With Neutral Ratings

Kaufman Bros. analyst Karl Keirsted has expanded his coverage of the on-demand software section, this morning picking up coverage of both NetSuite (N) and Taleo (TLEO) with Neutral ratings. On NetSuite, he sets a $12 target, a bit below the recent price. “The financials are not impressive relative to the peer group and the feedback […]

Read More →